Sugi Predict

Sugi Predict / Compounds / SCHEMBL2267290

SCHEMBL2267290

SCHEMBL2267290

c1ccc(OCC2CCCNC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ SLC6A2 P23975 3/20 0.57
▸ SLC6A4 P31645 3/20 0.57
▸ SLC6A3 Q01959 1/20 0.57
▸ CHRNB2 P17787 2/20 0.55
▸ CHRNA4 P43681 2/20 0.55
▸ IKBKB O14920 1/20 0.53
▸ CHUK O15111 1/20 0.53
▸ MAP2K1 Q02750 1/20 0.52
▸ CHRNB4 P30926 1/20 0.51
▸ CHRNA3 P32297 1/20 0.51
▸ EED O75530 1/20 0.50
▸ KMT2A Q03164 1/20 0.49
▸ LTA4H P09960 4/20 0.48
▸ KDM1A O60341 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3444195 1.00 SLC6A2 (0.57) SLC6A2SLC6A4SLC6A3CHRNB2CHRNA4
Hydrochloric Acid SCHEMBL9555741 0.98 SLC6A2 (0.56) SLC6A2SLC6A4SLC6A3CHRNB2CHRNA4
SCHEMBL1682660 0.91 CHRNB2 (0.56) SLC6A2SLC6A4SLC6A3CHRNB2CHRNA4
SCHEMBL35429 0.90 SLC6A2 (0.69) SLC6A2SLC6A4SLC6A3LTA4H
SCHEMBL27972144 0.90 SLC6A2 (0.69) SLC6A2SLC6A4SLC6A3LTA4H
Hydrochloric Acid SCHEMBL1682633 0.90 CHRNB2 (0.55) SLC6A2SLC6A4SLC6A3CHRNB2CHRNA4
SCHEMBL7327361 0.88 SLC6A2 (0.53) SLC6A2SLC6A4SLC6A3CHRNB2CHRNA4
SCHEMBL7327587 0.88 LTA4H (0.65) SLC6A2SLC6A4SLC6A3CHRNB2CHRNA4
Hydrochloric Acid SCHEMBL7325730 0.87 LTA4H (0.64) SLC6A2SLC6A4SLC6A3CHRNB2CHRNA4
Hydrochloric Acid SCHEMBL7328352 0.87 SLC6A2 (0.52) SLC6A2SLC6A4SLC6A3CHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240262832-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF VANQUA BIO, INC. (US) 2024-08-08 — — US disclosed
EP-4329881-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF Vanqua Bio, Inc. (US) 2024-03-06 — — EP disclosed
CN-117642404-A Small molecule modulators of glucocerebrosidase activity and uses thereof 凡况生化公司 2024-03-01 — — CN disclosed
WO-2022232383-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF VANQUA BIO, INC. (US) 2022-11-03 — — WO disclosed
EP-2607362-B1 Piperidine and piperazine carboxylates as FAAH inhibitors ASTELLAS PHARMA INC (JP) 2014-12-31 — — EP disclosed
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 — — US disclosed
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 — — US disclosed
EP-2607362-A1 Piperidine and piperazine carboxylates as FAAH inhibitors Astellas Pharma Inc. (JP) 2013-06-26 — — EP disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 — — US disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 — — US disclosed
US-20050080078-A1 Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter SEPRACOR, INC. (US) 2005-04-14 — — US disclosed
US-20040077706-A1 Ligands for monoamine receptors and transporters, and methods of use thereof AQUILA BRIAN M (US) 2004-04-22 — — US disclosed
EP-1318988-A2 LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF (NEUROTRANSMISSION) Sepracor, Inc. (US) 2003-06-18 — — EP disclosed
US-20030050309-A1 Ligands for monoamine receptors and transporters, and methods of use thereof SEPRACOR INC. 2003-03-13 — — US disclosed
WO-2002022572-A2 LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF (NEUROTRANSMISSION) SEPRACOR, INC. (US) 2002-03-21 — — WO disclosed
US-6262078-B1 Phenoxymethyl piperidine derivatives for the treatment of neuropathic pain SYNTEX (U.S.A.) LLC 2001-07-17 — — US disclosed
US-6110937-A A SODIUM CHANNEL BLOCKER TREATING AS LOCAL ANESTHETICS AND IN THE TREATMENT OF CARDIAC ARRHYTHMIAS SYNTEX USA, INC. (US) 2000-08-29 — — US disclosed
EP-0869119-A1 Phenoxymethyl piperidine derivatives being sodium channle blockers F. HOFFMANN-LA ROCHE AG (CH) 1998-10-07 — — EP disclosed
CN-1194977-A Phenoxymethyl piperidine derivatives HOFFMANN LA ROCHE (CH) 1998-10-07 — — CN disclosed
EP-0480794-A1 2-Aminopyrimidine-4-carboxamide derivatives, their preparation and therapeutic use SYNTHELABO (FR) 1992-04-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080078-A1 Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter PNMT, TAAR1, OPRL1 SLC6A2 12/4885SLC6A4 27/4885SLC6A3 8/4885
US-20030050309-A1 Ligands for monoamine receptors and transporters, and methods of use thereof SLC6A2, OPRL1, SLC18A2 SLC6A2 1/4885SLC6A4 13/4885SLC6A3 6/4885
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 SLC6A2 218/4885SLC6A4 207/4885SLC6A3 248/4885
US-20240262832-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF GBA1, GAA, GBA2 SLC6A2 1368/4885SLC6A4 2270/4885SLC6A3 571/4885
US-20040077706-A1 Ligands for monoamine receptors and transporters, and methods of use thereof SLC6A2, OPRL1, SLC18A2 SLC6A2 1/4885SLC6A4 13/4885SLC6A3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.